Sheth J, Bhavsar R, Mistri M, Pancholi D, Bavdekar A, Dalal A, et al. Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation. BMC Med Genet. 2019;20:31.

Article  PubMed  PubMed Central  Google Scholar 

Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.

Article  PubMed  PubMed Central  Google Scholar 

Vardi A, Zigdon H, Meshcheriakova A, Klein AD, Yaacobi C, Eilam R, et al. Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. J Pathol. 2016;239:496–509.

Article  CAS  PubMed  Google Scholar 

Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29:567–83.

Article  CAS  PubMed  Google Scholar 

Cox TM, Cachon-Gonzalez MB. The cellular pathology of lysosomal diseases. J Pathol. 2012;226:241–54.

Article  CAS  PubMed  Google Scholar 

Panicker LM, Miller D, Awad O, Bose V, Lun Y, Park TS, et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells. 2014;32:2338–49.

Article  CAS  PubMed  Google Scholar 

Kishnani PS, Al-Hertani W, Balwani M, Goker-Alpan O, Lau HA, Wasserstein M, et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab. 2022;135:154–62.

Article  CAS  PubMed  Google Scholar 

Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher’s disease. Expert Opin Pharmacother. 2008;9:1987–2000.

Article  CAS  PubMed  Google Scholar 

Murugesan V, Chuang W-L, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91:1082–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13:107–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab. 2013;108:56–64.

Article  CAS  PubMed  Google Scholar 

Badieyan ZS, Evans T. Concise review: application of chemically modified mRNA in cell fate conversion and tissue engineering. Stem Cells Transl Med. 2019;8:833–43.

Article  PubMed  PubMed Central  Google Scholar 

Nelson J, Sorensen EW, Mintri S, Rabideau AE, Zheng W, Besin G, et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv. 2020;6:eaaz6893.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaidyanathan S, Azizian KT, Haque A, Henderson JM, Hendel A, Shore S, et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids. 2018;12:530–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu S, Yang K, Li R, Zhang L. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21:6582.

Martini PGV, Guey LT. A new era for rare genetic diseases: messenger RNA therapy. Hum Gene Ther. 2019;30:1180–9.

Article  CAS  PubMed  Google Scholar 

Bernal JA. RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. J Cardiovasc Transl Res. 2013;6:956–68.

Article  PubMed  PubMed Central  Google Scholar 

Berraondo P, Martini PGV, Avila MA, Fontanellas A. Messenger RNA therapy for rare genetic metabolic diseases. Gut. 2019;68:1323–30.

Article  CAS  PubMed  Google Scholar 

An D, Frassetto A, Jacquinet E, Eybye M, Milano J, DeAntonis C, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine. 2019;45:519–28.

Article  PubMed  PubMed Central  Google Scholar 

Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118–e27.

Article  PubMed  PubMed Central  Google Scholar 

Polinski NK, Martinez TN, Gorodinsky A, Gareus R, Sasner M, Herberth M, et al. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model. PLOS ONE. 2021;16:e0252325.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, et al. CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA. 2011;108:12101–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol. 2003;163:2093–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y-H, Sun Y, Barnes S, Grabowski GA, Schiffmann R. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PloS ONE. 2010;5:e10750.

Article  PubMed  PubMed Central  Google Scholar 

Zheng W, Du S, Tian M, Xu W, Tian Y, Li T, et al. Lepidium meyenii Walp exhibits anti-inflammatory activity against ConA-induced acute hepatitis. Mediat Inflamm. 2018;2018:8982756.

Article  Google Scholar 

Ji YR, Kim HJ, Bae KB, Lee S, Kim MO, Ryoo ZY. Hepatic serum amyloid A1 aggravates T cell-mediated hepatitis by inducing chemokines via Toll-like receptor 2 in mice. J Biol Chem. 2015;290:12804–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Fost M, Aerts JM, Hollak CE. Gaucher disease: from fundamental research to effective therapeutic interventions. Neth J Med. 2003;61:3–8.

PubMed  Google Scholar 

Campbell TN, Choy FY. Knockdown of chimeric glucocerebrosidase by green fluorescent protein-directed small interfering RNA. Genet Mol Res. 2004;3:282–7.

CAS  PubMed  Google Scholar 

Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics. 2010;4:299–313.

CAS  PubMed  PubMed Central  Google Scholar 

Kido J, Sugawara K, Nakamura K. Gene therapy for lysosomal storage diseases: current clinical trial prospects. Front Genet. 2023;14:1064924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes DA, Ferrante F. GALILEO-1: a phase I/II safety and efficacy study of FLT201 gene therapy for Gaucher Disease Type 1. Future Rare Dis. 2023;3:FRD35.

Article  CAS  Google Scholar 

Rastall DP, Amalfitano A. Recent advances in gene therapy for lysosomal storage disorders. Appl Clin Genet. 2015;8:157–69.

CAS